Innovent Biologics Yönetim

Yönetim kriter kontrolleri 1/4

Innovent Biologics CEO'su Michael Yu, Jan2011 tarihinde atandı, in görev süresi 13.92 yıldır. in toplam yıllık tazminatı CN¥ 36.44M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.9% maaş ve 92.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 6.53% ine doğrudan sahiptir ve bu hisseler HK$ 3.77B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.9 yıl ve 3.3 yıldır.

Anahtar bilgiler

Michael Yu

İcra Kurulu Başkanı

CN¥36.4m

Toplam tazminat

CEO maaş yüzdesi	7.9%
CEO görev süresi	13.9yrs
CEO sahipliği	6.5%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Michael Yu'un ücretlendirmesi Innovent Biologics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥1b
Mar 31 2024	n/a	n/a	-CN¥1b
Dec 31 2023	CN¥36m	CN¥3m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥1b
Mar 31 2023	n/a	n/a	-CN¥2b
Dec 31 2022	CN¥33m	CN¥3m	-CN¥2b
Sep 30 2022	n/a	n/a	-CN¥2b
Jun 30 2022	n/a	n/a	-CN¥3b
Mar 31 2022	n/a	n/a	-CN¥3b
Dec 31 2021	CN¥26m	CN¥3m	-CN¥3b
Sep 30 2021	n/a	n/a	-CN¥2b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥1b
Dec 31 2020	CN¥105m	CN¥3m	-CN¥998m
Sep 30 2020	n/a	n/a	-CN¥1b
Jun 30 2020	n/a	n/a	-CN¥2b
Mar 31 2020	n/a	n/a	-CN¥2b
Dec 31 2019	CN¥76m	CN¥3m	-CN¥2b

Tazminat ve Piyasa: Michael 'nin toplam tazminatı ($USD 5.00M ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 848.16K ).

Tazminat ve Kazançlar: Michael şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Michael Yu (60 yo)

13.9yrs

Görev süresi

CN¥36,444,000

Tazminat

Dr. De-Chao Yu, also known as Michael, Ph.D. Co-Founded Innovent Biologics, Inc. in August 2011 and has been its Chairman and Chief Executive Officer since 2011. He served as its President at Innovent Biol...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
De-Chao Yu	Co-Founder	13.9yrs	CN¥36.44m	6.53% HK$ 3.8b
Hao Xi Ede	Executive Director & Fund Managing Partner	less than a year	CN¥7.10m	0.20% HK$ 114.6m
Fei You	Chief Financial Officer	less than a year	Veri yok	Veri yok
Vivian Zhang	Chief People Officer	5.4yrs	Veri yok	0.020% HK$ 11.8m
Min Liu	Chief Commercial Officer	no data	Veri yok	Veri yok
Dongming Wang	Senior Vice President	4.9yrs	Veri yok	Veri yok
Blake Salisbury	Senior Vice President	no data	Veri yok	Veri yok
Hui Zhou	Senior Vice President	less than a year	Veri yok	Veri yok
Nageatte Ibrahim	Oncology Chief Medical Officer	less than a year	Veri yok	Veri yok
Samuel Suhua Zhang	Global Chief Business Officer	less than a year	Veri yok	Veri yok
Raj Dhodda	Senior Vice President	less than a year	Veri yok	Veri yok
Yanju Wang	Joint Company Secretary	6.5yrs	Veri yok	Veri yok

0.9yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: 1801 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
De-Chao Yu	Co-Founder	13.9yrs	CN¥36.44m	6.53% HK$ 3.8b
Hao Xi Ede	Executive Director & Fund Managing Partner	no data	CN¥7.10m	0.20% HK$ 114.6m
Vivian Zhang	Chief People Officer	less than a year	Veri yok	0.020% HK$ 11.8m
Charles Leland Cooney	Member of CMC Strategic Advisory Board & Independent Non-Executive Director	9.2yrs	CN¥400.00k	0.0028% HK$ 1.6m
Lewis Lanier	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
I-Yin Hsu	Independent Non-Executive Director	6.2yrs	CN¥400.00k	0.00039% HK$ 224.9k
Erwin Vanhaecke	Member of CMC Strategic Advisory Board	no data	Veri yok	Veri yok
Kai-Xian Chen	Independent Non-Executive Director	6.2yrs	CN¥400.00k	0.00033% HK$ 190.3k
David LaPre	Member of CMC Strategic Advisory Board	no data	Veri yok	Veri yok
Shuyun Chen	Independent Non-Executive Director	less than a year	Veri yok	0.00067% HK$ 386.3k
Lawrence Fong	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Carlos Garcia-Echeverria	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1801 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/22 01:52
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Innovent Biologics, Inc. 53 Bu analistlerden 29, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Linda Lu	BOCI Research Ltd.
Wai Chak Yuen	BOCI Research Ltd.
Bo Li	BofA Global Research

Innovent Biologics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Co-Founder recently sold HK$81m worth of stock

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

High number of new directors

Co-Founder recently sold HK$37m worth of stock

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Recent updates

Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024

Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List

Co-Founder recently sold HK$81m worth of stock

First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023)

Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA

Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress

Forecast to breakeven in 2025

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023)

Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China

The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert

Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024

Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)

the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc

Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions

High number of new directors

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Co-Founder recently sold HK$37m worth of stock

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022)

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022)

Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer

Now 25% undervalued after recent price drop

Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease

Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee

Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints

China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib

Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351

Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib

Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care

The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients

Now 20% undervalued

Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor)

Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion.

Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion.

New minor risk - Shareholder dilution

First half 2023 earnings released: CN¥0.091 loss per share (vs CN¥0.65 loss in 1H 2022)

National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo

Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting

Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint

Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy

Full year 2022 earnings released: CN¥1.46 loss per share (vs CN¥2.16 loss in FY 2021)

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib

Forecast to breakeven in 2025

Innovent Biologics, Inc. Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress

Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity